Alebund Unveils Promising Phase 3 AP301 Trial Results at ASN 2025 Congress in Houston Alebund Pharmaceuticals presented significant Phase 3 trial results for AP301 at the ASN 2025 Congress, showcasing its ability to reduce serum phosphate levels effectively.

Alebund Unveils Promising Phase 3 AP301 Trial Results at ASN 2025 Congress in Houston #China #Houston #Alebund #AP301 #Hyperphosphatemia

Alebund Pharmaceuticals Achieves Success in Phase 3 Study of AP301 for Dialysis Patients Alebund Pharmaceuticals has shared promising results from its Phase 3 trial of AP301, a novel treatment for hyperphosphatemia in dialysis patients. The drug shows significant improvements in phosphorus control.

Alebund Pharmaceuticals Achieves Success in Phase 3 Study of AP301 for Dialysis Patients #China #Shanghai #Alebund #AP301 #Hyperphosphatemia

Alebund Pharmaceuticals Secures RMB 550 Million to Advance Innovative Kidney Treatments Alebund Pharmaceuticals announces a significant RMB 550 million Series C financing to enhance the development of its innovative renal therapies in China.

Alebund Pharmaceuticals Secures RMB 550 Million to Advance Innovative Kidney Treatments #China #Series_C_Funding #Alebund #renal_therapies #Yangzhou